Jbmune 500mg Tablet contains Mycophenolate sodium, an immunosuppressive agent primarily used to prevent organ transplant rejection. Mycophenolate sodium acts by selectively inhibiting inosine monophosphate dehydrogenase, a key enzyme in the de novo synthesis of guanine nucleotides, thereby suppressing the proliferation of T and B lymphocytes which are critical in the immune response. This mechanism helps reduce the risk of acute and chronic rejection episodes in patients undergoing renal, cardiac, or hepatic transplantation. Jbmune 500mg is typically administered as part of a combination immunosuppressive regimen, often alongside corticosteroids and calcineurin inhibitors, to enhance efficacy and minimize graft rejection. The tablet should be taken orally, preferably on an empty stomach to optimize absorption. Common adverse effects may include gastrointestinal disturbances such as nausea, vomiting, diarrhea, and abdominal pain, as well as hematological effects like leukopenia and anemia. Regular monitoring of blood counts and renal function is recommended during therapy. Jbmune 500mg is contraindicated in patients with known hypersensitivity to mycophenolate sodium and should be used cautiously in pregnant or breastfeeding women due to potential teratogenic effects. Proper adherence to prescribed dosing and follow-up is essential to maximize therapeutic outcomes and minimize complications.